LipiFlow Treatment for Meibomian Gland Dysfunction Approved by FDA
July 12, 2011
TearScience, Inc., announced yesterday that the FDA had cleared its LipiFlow® Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), one of the leading causes of dry eye. The clearance enables TearScience to market and sell LipiFlow® to eye care physicians in the U.S. LipiFlow® will be available immediately, but on a limited basis in the U.S. through the end of 2011. LipiFlow® removes meibomian gland obstructions by applying directed energy to a patient’s eyelid during a 12-minute in-office treatment.
Click here to learn more.
Jump down to form below to submit your own comments